Our mission is to conduct effective advocacy for public policies that encourage the discovery of important, new medicines for patients by biopharmaceutical research companies. To accomplish this mission, we are dedicated to achieving these goals in Washington, D.C. and across the country.

Featured Blogs

The dangers of expanding the TRIPS waiver

Megan Van Etten
Policymakers should reject any expansion of the TRIPS waiver and focus on last-mile distribution and administration challenges around the world to make a real impact.

New data: The 340B program is driving up costs for patients and our health care system

Nicole Longo
Fresh data show that 340B may actually be driving up costs for some patients and our health care system as whole.

Navigating the patient experience: Burdens and barriers standing between patients and their care

Mark Keida
Health care affordability is not the only hurdle facing patients, according to PhRMA’s third Patient Experience Survey (PES).